Description
CPI-006 is under investigation for its potential use in colorectal cancer (CRC) but has not yet been approved by the FDA or widely adopted in clinical practice. Its role in CRC treatment remains undefined and requires further research to establish efficacy and safety profiles.
Mechanism of Action
CPI-006 is an investigational agent that works by inhibiting the proteasome, a cellular complex involved in protein degradation and regulation of cell cycle progression.
Side Effects
Neutropenia; Fatiga; Náuseas; Vómitos
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT03454451
Phase 1
Archived
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
United States, Australia
Quick Info
| Category | Other Medications |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.